AI isn’t just shaping biotech narratives, it’s shifting the market

How could AI scaling, infrastructure spending, and shifting capital flows reshape the outlook for biotech investors?

Listen and subscribe on:

Apple PodcastsSpotify PodcastsGoogle Podcasts
By Rishi Jaluria and Leonid Timashev
Published | 3 min read

Key points

  • AI and biotech, once positively correlated, have recently begun moving inversely as capital shifts between the two sectors.
  • Biotech's defensive characteristics and smaller market weight may amplify the effects of capital rotating out of AI.
  • AI can support discovery, hypothesis generation, and research productivity, but it cannot replace scientific validation or regulatory review.
  • AI scaling, open-weight adoption, supply-chain disruption, and infrastructure spending could all influence biotech performance.

How has the relationship between AI and biotech changed?

Rishi Jaluria: AI is no longer just shaping biotech innovation narratives. Increasingly, it may also be influencing biotech market performance. In our recent report, Does Healthcare Dream of Electric Sheep?, published as part of the RBC Imagine research series, we explored how developments in AI could influence biotech through broader market dynamics and capital flows, as well as innovation itself.

Leonid Timashev: We wanted to understand whether AI was influencing biotech performance in ways investors were not fully appreciating. Historically, AI and biotech tended to move together, but our analysis showed that the relationship had recently turned inverse. While biotech's strong performance could be explained by traditional factors such as M&A activity, FDA flexibility, reduced concern around drug pricing, and a more favorable policy backdrop, the data also pointed to capital rotating out of AI and semiconductor stocks and into biotech.

It's hard to know whether this is temporary or structural. What we do know is that the shift is recent and appears strongest among larger-cap biotech names, which may be better positioned to absorb fund flows. Whether it endures will depend on factors affecting both markets, including AI's ability to continue scaling, biotech's defensive appeal, and the impact of rates and policy.

Why do AI shocks ripple through biotech?

Jaluria: When the AI trade comes under pressure, capital can rotate out of the higher-volatility technology complex and into more defensive parts of the market. Biotech can benefit from that dynamic because its performance is driven by a different set of factors and offers investors diversification from AI-related exposures. If those capital flows persist, weakness in AI could continue to support inflows into biotech, reinforcing the inverse relationship that has recently emerged between the two sectors.

Timashev: Biotech and pharma account for about 12% of the S&P 500, compared with approximately 50% for AI-related companies. Because biotech represents a much smaller part of the index, even a limited rotation out of AI can have a more visible effect on biotech performance. Given biotech's traditional defensive characteristics, some of those flows may reflect investors seeking shelter from volatility rather than growing conviction around sector-specific fundamentals.

Jaluria: More broadly, investors are increasingly thinking across themes rather than sectors. When the same pool of capital is moving rapidly between technology, AI, and healthcare, sector boundaries matter less. Investors can no longer assess biotech solely through a healthcare lens; they also need to understand the forces shaping capital allocation across technology, AI, and the wider market.

"Investors can no longer assess biotech solely through a healthcare lens."

Rishi Jaluria, U.S. Software Analyst, RBC Capital Markets

Where can AI create the most value in biotech?

Timashev: In our view, AI can have its greatest impact early in the development process. It can support molecule discovery and novel chemistry, generate hypotheses, and analyze large biological and chemical datasets to identify ideas worth testing. AI can also improve productivity in areas such as regulatory documentation, where submissions to the FDA often involve significant amounts of text and forms.

That said, some expectations around AI's impact remain unproven. Biotech breakthroughs still depend on scientific research, experimental validation, and regulatory review. While AI can improve efficiency, it cannot accelerate timelines that are fixed by regulatory requirements, such as mandated toxicity studies. We see AI as an important enabler of innovation, but not a substitute for the scientific discovery process itself.

"A lot of the underlying science still has to be done and verified. By humans."

Leonid Timashev, Biotechnology Analyst, RBC Capital Markets

What should biotech investors be watching?

Jaluria: We identified several AI-related risk dimensions that biotech investors should monitor. One is the potential for diminishing returns from compute scaling. If hyperscalers begin to experience diminishing returns, biotech could benefit from a rotation of capital out of AI, potentially supporting gains of 15% to 20%. If performance continues to improve and commercial adoption accelerates, we would expect a gradual rotation back toward AI, potentially contributing to a 15% to 25% contraction in biotech.

Another key variable is the extent to which open-weight models challenge token-based pricing and the premium economics of the AI ecosystem. If open-weight adoption grows aggressively, it could pressure hyperscalers’ peak revenue expectations and support a rotation into biotech. Conversely, if regulatory restrictions reduce open-weight usage, stronger AI-related performance could contribute to capital moving back out of biotech.

Investors should also watch geopolitical, cybersecurity, regulatory, and capital-spending risks. A normalization in shipping could accelerate AI infrastructure investment and pressure biotech, while prolonged disruption could modestly benefit the sector. A rise in AI-related cybersecurity incidents could also increase regulatory scrutiny and potentially support biotech. In our analysis, a slowdown in AI capital expenditure could contribute to 10% to 15% upside for biotech, while continued or accelerated investment could create 5% to 10% downside pressure.

View audio transcript

Our experts

Rishi Jaluria
Rishi Jaluria
U.S. Software Analyst, RBC Capital Markets
Leonid Timashev
Leonid Timashev
Biotechnology Analyst, RBC Capital Markets

 

Stay informed

Get the latest insights and news from RBC Capital Markets delivered to your inbox.